Press release
Biomed Industries to Present Groundbreaking Research at AD/PD™ 2024 International Conference
Biomed Industries
The presentations by Biomed include:
• Neurogenesis and Clinical Trials Of NA-831 for Alzheimer's Disease and Major Depressive Disorder
• A Phase 3 Clinical Protocol to Study the Safety and Efficacy Of NA-831 in Combination with Lecanemab In Subjects with Early Alzheimer's Disease
• What does Amyloid-Beta (Aβ) have to do with Alzheimer's Disease? A History of Failure
AD/PD™ 2024 attracts leading medical and scientific professionals worldwide and serves as a pivotal platform for disseminating cutting-edge research on Alzheimer's, Parkinson's, and related neurodegenerative diseases. The conference, renowned for its exploration of disease mechanisms and advancements in treatment, emphasizes prevention and therapy strategies across various neurodegenerative conditions.
"We are excited to present our research on Neurogenesis as a rapidly emerging alternative to current therapeutic approaches in Alzheimer's Disease. Both the safety and efficacy of NA-831 in our Phase 2 clinical trial has shown results that far exceed the recently FDA approved drugs for AD." said Lloyd Tran, Founder and CEO of Biomed Industries. He continued: "As it has become increasingly clear that new approaches are needed, we stand at the forefront of this new frontier."
Biomed is soon to conduct a Phase 2B Alzheimer's Disease (AD) trial and a Phase 3 trial of NA-831 for Major Depressive Disorder (MDD), with plan seek FDA approval of NA-831 for treatment of both AD and MDD.
Michael Willis
Biomed Industries, Inc.
San Jose, CA 95131 USA
Tel. 800-824-5135
Email: media@biomedind.com
About Biomed Industries, Inc.:
Biomed Industries, Inc. is a pioneering bio-pharmaceutical company dedicated to developing and commercializing novel drug therapeutics to address unmet medical needs. The company's research team has developed a new platform of drugs targeting Alzheimer's disease, Major Depressive Disorder (MDD), Diabetes Obesity, and rare diseases, including Rett Syndrome and Fragile X.
For further information, please visit Biomed Industries' official website: https://www.biomedind.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Biomed Industries to Present Groundbreaking Research at AD/PD™ 2024 International Conference here
News-ID: 3410534 • Views: …
More Releases from Biomed Industries
Biomed Industries Announces Results of Phase 1B Pilot Study for Treatment of Dep …
Biomed Industries, Inc. (Biomed) announced results today from its Phase 1B clinical trial of NA-831 for the treatment of Major Depressive Disorder (MDD). The Phase 1B pilot study was a randomized, double-blind, fixed-dose, placebo-controlled, active reference study to investigate the efficacy, safety, and tolerability of two fixed doses (20 and 40 mg/d) of NA-831 vs. placebo after 6-week treatment in 32 adult patients with major depressive disorder (MDD). Venlafaxine XR…
More Releases for Alzheimer
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion.
Data Bridge…
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly…
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
Global Alzheimer Market Report: 2015 Edition | Now Available at Researchmoz.us
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports.
Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as…
